Roche, in collaboration with Eli Lilly, has received CE Mark approval for the Elecsys pTau217 assay, a blood-based test designed to detect phosphorylated Tau (pTau) 217, a key biomarker associated with amyloid pathology and Alzheimer’s disease.
This development could significantly reshape the Alzheimer’s diagnostic pathway.
Why this matters?
Today, Alzheimer’s diagnosis often depends on:
· PET scans
· Cerebrospinal fluid (CSF) testing
· Specialist referrals and lengthy wait times
These methods are expensive, invasive, and inaccessible for many patients globally. As a result:
· Around 41 million people living with dementia remain undiagnosed worldwide
· Patients wait an average of 3.5 years after symptoms first appear before receiving a diagnosis
A scalable blood-based diagnostic has the potential to change that equation.
Strategic implications for healthcare systems:
Roche’s pTau217 test introduces several transformative advantages:
1) Earlier detection in routine care settings
The ability to use the same diagnostic cutoffs across both primary and secondary care could enable broader adoption and faster clinical decision-making.
2) Reduced burden on healthcare infrastructure
Blood-based testing may help reduce dependency on specialist imaging and invasive procedures, easing pressure on constrained healthcare systems.
3) Improved patient outcomes
Earlier identification of amyloid pathology allows patients and families to:
· Access treatment pathways sooner
· Participate in care planning earlier
· Benefit from emerging disease-modifying therapies at more effective stages
A broader industry shift:
The approval also signals a larger transition underway in neuroscience and diagnostics:
· Moving Alzheimer’s detection from specialised centres into mainstream clinical practice
· Expanding precision diagnostics through minimally invasive testing
· Accelerating the convergence of biotech, diagnostics, and AI-driven disease management
As the industry advances toward earlier intervention models, blood-based biomarkers such as pTau217 may become foundational to the future standard of care in neurodegenerative disease management.